Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;63(4):273-8.
doi: 10.1007/s13224-012-0342-6. Epub 2013 Mar 12.

The efficacy and safety of neoadjuvant chemotherapy in treatment of locally advanced carcinoma cervix

Uma Singh  1 , Neetu Ahirwar  1 , Anju Kumari Rani  2 , Nisha Singh  1 , Pushplata Sankhwar  1 , Sabuhi Qureshi  1
Affiliations

The efficacy and safety of neoadjuvant chemotherapy in treatment of locally advanced carcinoma cervix

Uma Singh et al. J Obstet Gynaecol India. 2013 Aug.

Abstract

Objective: A prospective cohort study in a teaching hospital to assess the efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced carcinoma cervix.

Method: Neoadjuvant chemotherapy in the form of cisplatin 75 mg/m(2) and paclitaxel 135 mg/m(2) on day 1 and repeated at 14 days' interval for up to a maximum of three courses.

Results: Neoadjuvant chemotherapy in cervical cancer was effective in the downstaging of the disease. Downstaging was observed in 19.23 % of patients after two cycles and in 50 % of patients after three cycle of NACT. Operability increases to 33.3 and 38.4 % after two and three cycles of NACT, respectively. Complete pathological response was observed in 37.5 % of patients after NACT. No significant adverse effect in the feasibility of surgery was observed.

Conclusion: The present study showed that neoadjuvant chemotherapy was an effective and well-tolerated mode of therapy with significantly less morbidity and mortality.

Keywords: Cervical cancer; Downstaging; Neoadjuvant chemotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall downstaging observed after NACT
See this image and copyright information in PMC

References

    1. Poveda A, Martin AG. Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update. Ann Oncol. 2008;19:70–76. doi: 10.1093/annonc/mdn465. - DOI - PubMed
    1. Rose PG. Combined-modality therapy of locally advanced cervical cancer. J Clin Oncol. 2003;21:211s–217s. doi: 10.1200/JCO.2003.01.222. - DOI - PubMed
    1. Green JA, Klirwan JM, Tierney JF, Symnds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–786. doi: 10.1016/S0140-6736(01)05965-7. - DOI - PubMed
    1. Gonzalez AD, Cetina L, Mariscal I, Garza J. Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003;29:389–399. doi: 10.1016/S0305-7372(03)00068-9. - DOI - PubMed
    1. Gonzalez AD, Lopea-Graniell CM, Mota A, Mohar A. Neoadjuvant chemotherapy followed by surgery in locally advanced cervical carcinoma. J Clin Oncol. 2002;20:2908–2910. - PubMed

LinkOut - more resources